找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals; John Geigert Book 2023Latest edition The Editor(s) (if applicable) and

[復(fù)制鏈接]
查看: 40877|回復(fù): 35
樓主
發(fā)表于 2025-3-21 18:19:49 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
編輯John Geigert
視頻videohttp://file.papertrans.cn/906/905839/905839.mp4
概述Updates real-world CMC deficiency examples with current examples.Addresses current FDA and EMA requirements and expectations for CMC regulatory compliance.Now includes CMC regulatory compliance for th
圖書封面Titlebook: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals;  John Geigert Book 2023Latest edition The Editor(s) (if applicable) and
描述Each year for the past three years, there have been about 50 new molecular medicines approved by the United States Food & Drug Administration (FDA), of which approximately 25% were new biopharmaceuticals. Over 200 recombinant proteins, monoclonal antibodies, antibody drug conjugates, fusion proteins, and Fab fragments are now in the marketplace in both the United States of America (USA) and European Union (EU). There are also now over 60 biosimilars available for all major classes of recombinant proteins and monoclonal antibodies. In addition, gene therapies using genetically engineered viruses and genetically engineered cells are now in the marketplace, and continually growing. This degree of change is reflected in the over 400 CMC regulatory compliance references listed in this book that were either issued or updated since the release of the third edition.?.Deficiencies in biopharmaceutical CMC regulatory compliance rarely result in termination of a product, but incan readily cause months if not years of delay in initiating clinical trials, or advancing clinical development stages, or even market approval..In summary, this book:.Updates real-world CMC deficiency examples with cur
出版日期Book 2023Latest edition
關(guān)鍵詞biopharmaceutical; monoclonal antibodies; in vivo and ex vivo gene therapy; engineered antibodies; biosi
版次4
doihttps://doi.org/10.1007/978-3-031-31909-9
isbn_softcover978-3-031-31911-2
isbn_ebook978-3-031-31909-9
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals影響因子(影響力)




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals影響因子(影響力)學(xué)科排名




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals網(wǎng)絡(luò)公開度




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals被引頻次




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals被引頻次學(xué)科排名




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals年度引用




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals年度引用學(xué)科排名




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals讀者反饋




書目名稱The Challenge of CMC Regulatory Compliance for Biopharmaceuticals讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:12:32 | 只看該作者
第105839主題貼--第2樓 (沙發(fā))
板凳
發(fā)表于 2025-3-22 03:19:56 | 只看該作者
板凳
地板
發(fā)表于 2025-3-22 04:39:56 | 只看該作者
第4樓
5#
發(fā)表于 2025-3-22 12:24:55 | 只看該作者
5樓
6#
發(fā)表于 2025-3-22 13:06:20 | 只看該作者
6樓
7#
發(fā)表于 2025-3-22 19:57:43 | 只看該作者
7樓
8#
發(fā)表于 2025-3-22 21:32:14 | 只看該作者
8樓
9#
發(fā)表于 2025-3-23 02:18:52 | 只看該作者
9樓
10#
發(fā)表于 2025-3-23 06:43:11 | 只看該作者
10樓
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 08:37
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
乌恰县| 无为县| 板桥市| 铜鼓县| 宁武县| 城步| 瓦房店市| 江油市| 临高县| 阳曲县| 泰来县| 兰溪市| 明水县| 正蓝旗| 浮山县| 平武县| 怀仁县| 甘德县| 张家界市| 武山县| 曲麻莱县| 桐柏县| 馆陶县| 晋宁县| 依兰县| 乳源| 龙海市| 黑山县| 清原| 淳安县| 江津市| 房山区| 苍溪县| 顺义区| 宜兴市| 桂东县| 古浪县| 轮台县| 大姚县| 沿河| 合作市|